Drugs / SPR741
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03376529 | Nov → Dec 2017 | — | Spero Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03022175 | Dec 2016 → Jul 2017 | — | Spero Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPR741 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03022175 ↗ |
| Known as | NAB-741 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1631770 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL1631770 ↗ |
| Route | Intravenous | “single and multiple intravenous doses of SPR741” NCT03022175 ↗ |